cancer
70 stories · Page 2 of 3
Keto Raised Tumor Counts in One Stretch of Mouse Gut and Cut Them in the Next, While the Ketones Sat It Out
In cancer-prone mice, a ketogenic diet meant more small-intestine tumors and fewer colon tumors, and the ketones long credited for keto's anticancer promise turned out to be bystanders.
Drugs & FDAGaming a Cancer Trial Is 'Cheap and Easy,' Says a Former Top FDA Official
Vinay Prasad says nobody needs AI to fake a phase 3 cancer win, and a Mayo Clinic audit found 16 of 96 FDA cancer approvals rested on control arms its authors judged suboptimal.
CancerThe 80.5 Percent Headline, and the Three Confirmed Responses Behind It
Vividion led its colorectal announcement with an 80.5 percent disease-control rate. In that same group, three tumors shrank enough to count as a response.
CancerThe Compound That Outsmarts Cancer's Defenses: Eight Cell Lines, a Few Mice, and a Startup
Baylor researchers say CS18 dismantles the survival switch tumors use to resist treatment. It works in eight cell lines and a handful of mice, and its inventors just incorporated a company around it.
CancerThe Healing Cells That Cheat Death Carry a Catch: Their Offspring Are Seven Times Harder to Kill
A radiation-blasted fruit fly rebuilt half its ruined tissue in two days, and the cells that pulled it off left descendants 7 times harder to kill, which may be close to how some tumors outlast the treatments meant to finish them.
CancerThe Mesothelioma Drug in This Month's Headlines Was Tested in Fifteen People
The scientist whose lab found the drug's target is also chief science officer of the company selling it, a conflict the breakthrough headlines tuck into a job title.
CancerYounger Generations Are Testing Biologically Older, and Early Cancer Is Tracking the Gap
By a nine-marker blood panel, Americans born in the 1990s scored biologically older than those born in the late 1960s did at the same age, and Washington University researchers found that accelerated aging tracked a higher risk of early-onset cancer.
CancerA Top Cancer Researcher Logged 333 Tumor Reports After COVID Shots and Infection. Now He Wants the Study the Agencies Won't Fund.
Wafik El-Deiry helped map how the p53 gene guards against cancer. Now he has co-authored a review of 333 tumor reports that surfaced or came roaring back after COVID vaccination or infection, plus a blunt admission that no one has produced the population study to rule the vaccine link out.
Drugs & FDAThe FDA Approved a Breast Cancer Drug Its Own Advisers Had Just Rejected, 6 to 3
An FDA advisory panel voted 6 to 3 that AstraZeneca had not shown its breast cancer drug delivered a meaningful benefit. The agency approved it four months later anyway.
CancerMD Anderson Made the Case for Radiation Cleanup After Immunotherapy. Then Its Own Trial Undercut It.
In the oligometastatic subgroup the strategy was built for, small and underpowered, the patients who added radiation trended the wrong way: median survival of 42 months against 75.8 for the drugs alone.
CancerUCLA Can Grow Thousands of Cancer-Fighting Cell Doses in Six Weeks. Every Patient So Far Has Been a Mouse.
The lab put a $5,000-a-dose price on an off-the-shelf cancer therapy grown from cord blood that controlled tumors in mice with ovarian cancer and melanoma. No human has received it.
CancerSummit's $500 Million Lung Drug Split the Curve Patients Can't Feel
Ivonescimab delayed tumor progression by 2.4 months in EGFR-mutated lung cancer, but its overall-survival curve never cleared statistical significance and serious treatment-related adverse events nearly doubled.
CancerFused Into One Cell, a Neutrophil and a Macrophage Ate Tumors Two Ways
CAR-macrophage therapy keeps stalling in solid tumors: it can't get in, and it can't finish. Fuse a neutrophil onto it and, in mice, one dose shrank the tumor and kept it from coming back.
Drugs & FDAThe FDA Approved a Breast Cancer Drug Four Months After Its Advisers Voted No
On April 30 the FDA's oncology advisers voted 6 to 3 that AstraZeneca's camizestrant hadn't shown a clinically meaningful benefit. On September 4 the agency approved it anyway, conceding in its own approval that the benefit is "not yet confirmed."
CancerDecades of Cancer Warning Signs, and Still No Proof They Save Lives
England's cancer-awareness campaigns sent more people to the doctor for a decade. The reviews still can't show they caught a single cancer earlier or cut deaths, while the cancers that kill fastest stay silent until it's already too late.
CancerHigh Blood Sugar Hands Cancer Cells a Cloak the Immune System Can't See Through
Grown in a fluid built to mimic the human body, cancer cells used excess glucose to thicken a sugar coating that hid them from immune cells, an effect that never showed up in the standard lab dishes used across cancer biology.
Drugs & FDAThe Pancreatic-Cancer Pill That Doubles Survival: $39,800 a Month, and a Fast Lane Congress Never Approved
Rasonque roughly doubles median survival in metastatic pancreatic cancer. Revolution Medicines priced it at $477,600 a year, more than double Keytruda, and the FDA cleared it early through a voucher program lawmakers say Congress never authorized.
CancerA New Cancer 'Weapon' That Has Only Ever Slowed Tumors in Mice
Stanford's tissue-resident natural killer cells slowed melanoma and head-and-neck tumors in mice. John Sunwoo warned against reading too much into that. The coverage read plenty into it anyway.
CancerUC Irvine's 'Framework' for Safer CAR-T Is a Hypothesis Essay, Not a Study
The senior author consults for Kite Pharma, whose Yescarta accounted for all 6 grade-5 neurotoxicity deaths in the cited review's real-world data, the exact harm the paper proposes to treat.
CancerThe Cells That Heal Wounds Are Feeding Breast Cancer Its Nerves
University of Oklahoma researchers blocked the protein in mice and triple-negative tumors grew far less. In patients, all they have is a correlation and a drug, already sold for something else, that has never been tried against breast cancer.
CancerThe Cancer Trials That Buried Vitamin C Never Put It in a Vein
Mayo's famous trials gave advanced cancer patients vitamin C by mouth and found nothing. A randomized trial that delivered it by IV, at a dose pills cannot reach, doubled survival in metastatic pancreatic cancer.
Drugs & FDAThe FDA Twice Called This Melanoma Trial Uninterpretable. Then It Approved the Drug, at $450,000 a Course.
Federal reviewers rejected Replimune's melanoma therapy twice, faulting a single-arm trial they called not adequate and well-controlled and its results uninterpretable. No new controlled data ever answered them. After a 10-3 advisory vote, the FDA approved it anyway, at $450,000 a course.
Nutrition & FoodCancer Drugs Starve Tumors of Arginine. A Rockefeller Lab Says the Immune System May Need It to See Them.
Some cancer therapies deliberately strip arginine from the body to starve tumors. Rockefeller researchers found that in mice the same depletion can hide tumors, flu, and SARS-CoV-2 from the immune system.
CancerThe Reason Immunotherapy Bounces Off Prostate Cancer: Tumors Chew Off a Genetic Tail to Blind the Immune System
Prostate tumors overproduce a protein that destroys the immune system's docking targets. A CRISPR tool that blocks the trick made checkpoint drugs work again, so far only in mice.